Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

NCT03798054 ·Status: COMPLETED ·Phase: PHASE3

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

NCT01499095 ·Status: COMPLETED ·Phase: PHASE3

Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients

NCT01206712 ·Status: COMPLETED

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

NCT01484262 ·Status: COMPLETED

Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

NCT01596504 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

NCT02752412 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

NCT02749890 ·Status: COMPLETED ·Phase: PHASE3

Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy

NCT02855684 ·Status: COMPLETED ·Phase: PHASE3

Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)

NCT00642915 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

NCT01973231 ·Status: COMPLETED ·Phase: PHASE4

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

NCT01500850 ·Status: UNKNOWN ·Phase: PHASE4

A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants

NCT01476345 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

NCT01768559 ·Status: COMPLETED ·Phase: PHASE3

An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice

NCT00576368 ·Status: COMPLETED ·Phase: PHASE4

A Study of LY2963016 in Healthy Participants

NCT01634165 ·Status: COMPLETED ·Phase: PHASE1

PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes

NCT02506647 ·Status: COMPLETED ·Phase: PHASE1

A Study in Adults With Type 2 Diabetes

NCT01421459 ·Status: COMPLETED ·Phase: PHASE3

A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus

NCT04957914 ·Status: COMPLETED ·Phase: PHASE1

Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany

NCT00665808 ·Status: COMPLETED

Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment

NCT00046462 ·Status: COMPLETED ·Phase: PHASE3

Lantus in Prediabetes

NCT00348972 ·Status: COMPLETED ·Phase: PHASE1

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

NCT03338023 ·Status: COMPLETED ·Phase: PHASE3

Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®

NCT00806897 ·Status: COMPLETED

A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants

NCT03286751 ·Status: COMPLETED ·Phase: PHASE1

Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

NCT00097500 ·Status: COMPLETED ·Phase: PHASE3